Related references
Note: Only part of the references are listed.Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review
G. Fond et al.
ACTA PSYCHIATRICA SCANDINAVICA (2014)
Serological Documentation of Maternal Influenza Exposure and Bipolar Disorder in Adult Offspring
Sarah E. Canetta et al.
AMERICAN JOURNAL OF PSYCHIATRY (2014)
Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function
Arsime Demjaha et al.
BIOLOGICAL PSYCHIATRY (2014)
A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)
Oliver D. Howes et al.
BRITISH JOURNAL OF PSYCHIATRY (2014)
Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate
Guillaume Fond et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2014)
Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli
Darragh Duffy et al.
IMMUNITY (2014)
Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients
Hans Rasmussen et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii
Hui-Ling Wang et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2014)
Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis
S. Smesny et al.
MOLECULAR PSYCHIATRY (2014)
Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid
J. J. Luykx et al.
MOLECULAR PSYCHIATRY (2014)
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment
Antonio Drago et al.
PHARMACOGENETICS AND GENOMICS (2014)
Activation of Th17 cells in drug naive, first episode schizophrenia
Minli Ding et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
Effects of vitamin D receptor polymorphisms on the risk of schizophrenia and metabolic changes caused by risperidone treatment
Pei Jiang et al.
PSYCHIATRY RESEARCH (2014)
Morning cortisol levels in schizophrenia and bipolar disorder: A meta-analysis
Leah Girshkin et al.
PSYCHONEUROENDOCRINOLOGY (2014)
Cortisol awakening response and diurnal cortisol among children at elevated risk for schizophrenia: Relationship to psychosocial stress and cognition
Alexis E. Cullen et al.
PSYCHONEUROENDOCRINOLOGY (2014)
Impaired Metabolic Reactivity to Oxidative Stress in Early Psychosis Patients
Margot Fournier et al.
SCHIZOPHRENIA BULLETIN (2014)
Reduced Levels of Vasopressin and Reduced Behavioral Modulation of Oxytocin in Psychotic Disorders
Leah H. Rubin et al.
SCHIZOPHRENIA BULLETIN (2014)
The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia
Kenneth L. Subotnik et al.
SCHIZOPHRENIA RESEARCH (2014)
Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment
Lot de Witte et al.
SCHIZOPHRENIA RESEARCH (2014)
A longitudinal study on the relationship between duration of untreated psychosis and executive function in early-onset first-episode psychosis
David Fraguas et al.
SCHIZOPHRENIA RESEARCH (2014)
Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Rachel Upthegrove et al.
SCHIZOPHRENIA RESEARCH (2014)
Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis. A 2-year follow-up study
Monica Martinez-Cengotitabengoa et al.
SCHIZOPHRENIA RESEARCH (2014)
Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial
Fang Liu et al.
SCHIZOPHRENIA RESEARCH (2014)
Duration of untreated bipolar disorder: missed opportunities on the long road to optimal treatment
N. Drancourt et al.
ACTA PSYCHIATRICA SCANDINAVICA (2013)
Cortisol Levels and Risk for Psychosis: Initial Findings from the North American Prodrome Longitudinal Study
Elaine F. Walker et al.
BIOLOGICAL PSYCHIATRY (2013)
Serum and gene expression profile of cytokines in first-episode psychosis
Marco Di Nicola et al.
BRAIN BEHAVIOR AND IMMUNITY (2013)
Pharmacogenetics of antipsychotics: recent progress and methodological issues
Jian-Ping Zhang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation
Karina S. MacDowell et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Innovative solutions to novel drug development in mental health
T. R. Insel et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2013)
Distinct Molecular Phenotypes in Male and Female Schizophrenia Patients
Jordan M. Ramsey et al.
PLOS ONE (2013)
Extended duration of hospitalization in first episode psychosis: An evaluation of its clinical justification
Delphine Capdevielle et al.
PSYCHIATRY RESEARCH (2013)
Skin Ceramide Alterations in First-Episode Schizophrenia Indicate Abnormal Sphingolipid Metabolism
Stefan Smesny et al.
SCHIZOPHRENIA BULLETIN (2013)
Polyunsaturated Fatty Acid Concentration Predicts Myelin Integrity in Early-Phase Psychosis
Bart D. Peters et al.
SCHIZOPHRENIA BULLETIN (2013)
CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence
Dana Ravyn et al.
SCHIZOPHRENIA RESEARCH (2013)
Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis
Valerie Tourjman et al.
SCHIZOPHRENIA RESEARCH (2013)
Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight
Xueqin Song et al.
SCHIZOPHRENIA RESEARCH (2013)
Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis
Leah H. Rubin et al.
SCHIZOPHRENIA RESEARCH (2013)
The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls
Xiaoli Wu et al.
SCHIZOPHRENIA RESEARCH (2013)
Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia
Arsime Demjaha et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment
Oliver D. Howes et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism
Alan S. Brown
DEVELOPMENTAL NEUROBIOLOGY (2012)
Oxytocin Revisited: Its Role in Cardiovascular Regulation
J. Gutkowska et al.
JOURNAL OF NEUROENDOCRINOLOGY (2012)
Metabolomic Analysis of Biochemical Changes in the Plasma and Urine of First-Episode Neuroleptic-Naive Schizophrenia Patients after Treatment with Risperidone
Hua-Lin Cai et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse
Milica Borovcanin et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2012)
Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?
S. Kapur et al.
MOLECULAR PSYCHIATRY (2012)
Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia
Emily G. Severance et al.
NEUROBIOLOGY OF DISEASE (2012)
Update on Omega-3 Polyunsaturated Fatty Acids in Early-Stage Psychotic Disorders
G. Paul Amminger et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
Alice Egerton et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Treating patients with schizophrenia deficit with erythropoietin?
Guillaume Fond et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2012)
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis
Benedicto Crespo-Facorro et al.
PSYCHOPHARMACOLOGY (2012)
Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update
E. Fuller Torrey et al.
SCHIZOPHRENIA BULLETIN (2012)
Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study
David Fraguas et al.
SCHIZOPHRENIA RESEARCH (2012)
Early intervention in schizophrenia in developing countries: Focus on duration of untreated psychosis and remission as a treatment goal
Bonginkosi Chiliza et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2012)
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Brian J. Miller et al.
BIOLOGICAL PSYCHIATRY (2011)
Reduced antioxidant defense in early onset first-episode psychosis: a case-control study
Juan Antonio Mico et al.
BMC PSYCHIATRY (2011)
Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients
Monia Raffa et al.
BMC PSYCHIATRY (2011)
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia
Ruth Condray et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Evaluation of Five Antischizophrenic Agents Against Toxoplasma gondii in Human Cell Cultures
David G. Goodwin et al.
JOURNAL OF PARASITOLOGY (2011)
Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis
Belinda Garner et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2011)
Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine
Andreas Meyer-Lindenberg et al.
NATURE REVIEWS NEUROSCIENCE (2011)
Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis
Jose Maria Pelayo-Teran et al.
PSYCHIATRY RESEARCH (2011)
Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis
M. Aas et al.
PSYCHOLOGICAL MEDICINE (2011)
Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders A Randomized, Placebo-Controlled Trial
G. Paul Amminger et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis
Rainald Moessner et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2010)
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na⟨ve patients with first-episode schizophrenia treated with risperidone
Nikolina Jovanovic et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Yechiel Levkovitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
Todd Lencz et al.
PHARMACOGENETICS AND GENOMICS (2010)
Reduced folic acid, vitamin B-12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: Implications for altered one-carbon metabolism
Anvita Kale et al.
PSYCHIATRY RESEARCH (2010)
Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis
Javier Vazquez-Bourgon et al.
PSYCHIATRY RESEARCH (2010)
Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study
Stephen J. Wood et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2010)
Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment
Norbert Mueller et al.
SCHIZOPHRENIA RESEARCH (2010)
Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis
Valeria Mondelli et al.
SCHIZOPHRENIA RESEARCH (2010)
A Danish National Birth Cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring
Preben B. Mortensen et al.
SCHIZOPHRENIA RESEARCH (2010)
Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment
Valeria Mondelli et al.
SCHIZOPHRENIA RESEARCH (2010)
Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis
Swapna Verma et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2009)
Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging
O. D. Howes et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
DHEA and DHEA-S levels in hospitalized adolescents with first-episode schizophrenia and conduct disorder: A comparison study
Rael D. Strous et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis
Swapna K. Verma et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Common variants on chromosome 6p22.1 are associated with schizophrenia
Jianxin Shi et al.
NATURE (2009)
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
Shaun M. Purcell et al.
NATURE (2009)
Common variants conferring risk of schizophrenia
Hreinn Stefansson et al.
NATURE (2009)
Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients
Immaculada Baeza et al.
PSYCHIATRY RESEARCH (2009)
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia
Masashi Ikeda et al.
PHARMACOGENOMICS (2008)
Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors
Tzu-Hua Wu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Are metabolic indices different between drug-naive first-episode psychosis patients and healthy controls?
Sarojini Sengupta et al.
SCHIZOPHRENIA RESEARCH (2008)
Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial
Gregor E. Berger et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol:: An open-label pilot study
E. Y. Sivrioglu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
The principle of homeostasis in the hypothalamus-pituitary-adrenal system: new insight from positive feedback
A. Peters et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2007)
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro
Jeannine S. Strobl et al.
JOURNAL OF PARASITOLOGY (2007)
Antibodies to infectious agents in individuals at ultra-high risk for psychosis
G. Paul Amminger et al.
BIOLOGICAL PSYCHIATRY (2007)
Early infections of Toxoplasma gondii and the later development of schizophrenia
Preben Bo Mortensen et al.
SCHIZOPHRENIA BULLETIN (2007)
Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients
Gavin P. Reynolds et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Metabolic profiling of CSF: Evidence that early intervention may impact on disease progression and outcome in schizophrenia
Elaine Holmes et al.
PLOS MEDICINE (2006)
Biomarkers of cardiovascular disease - Molecular basis and practical considerations
Ramachandran S. Vasan
CIRCULATION (2006)
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients
T Lencz et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Mate patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release
P Walsh et al.
PSYCHONEUROENDOCRINOLOGY (2005)
Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring
AS Brown et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response
GP Reynolds et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Psychopathology in first-episode schizophrenia and antibodies to Toxoplasma gondii
S Bachmann et al.
PSYCHOPATHOLOGY (2005)
Antibodies to infectious agents in individuals with recent onset schizophrenia
FM Leweke et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2004)
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients
B Arranz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Evidence of basal pituitary-ad renal overactivity in first episode, drug naive patients with schizophrenia
MCM Ryan et al.
PSYCHONEUROENDOCRINOLOGY (2004)
Serologic-evidence of prenatal influenza in the etiology of schizophrenia
AS Brown et al.
ARCHIVES OF GENERAL PSYCHIATRY (2004)
Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology
RD Strous et al.
SCHIZOPHRENIA RESEARCH (2004)
Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline
RD Reddy et al.
SCHIZOPHRENIA BULLETIN (2004)
Atypical antipsychotics and the relevance of glutamate and serotonin
FMMA van der Heijden et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2004)
Reduced plasma antioxidants in first-episode patients with schizophrenia
R Reddy et al.
SCHIZOPHRENIA RESEARCH (2003)
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol
JA Lieberman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii
L Jones-Brando et al.
SCHIZOPHRENIA RESEARCH (2003)
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
G Zalsman et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2003)
Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain
GP Reynolds et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia
R Yoshimura et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2003)
Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia
MCM Ryan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics
MM Khan et al.
SCHIZOPHRENIA RESEARCH (2002)
Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism
GP Reynolds et al.
LANCET (2002)
Maternal infections and subsequent psychosis among offspring
SL Buka et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Share Paper
